View Item 

Show simple item record

Guidelines for pediatric management of severe chronic neutropenia

dc.contributor.authorDale, David C.en_US
dc.contributor.authorBoxer, Laurence A.en_US
dc.date.accessioned2012-03-16T16:02:01Z
dc.date.available2013-04-01T14:17:26Zen_US
dc.date.issued2012-02en_US
dc.identifier.citationDale, David C.; Boxer, Laurence A. (2012). "Guidelines for pediatric management of severe chronic neutropenia ." American Journal of Hematology 87(2): 133-133. <http://hdl.handle.net/2027.42/90415>en_US
dc.identifier.issn0361-8609en_US
dc.identifier.issn1096-8652en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90415
dc.publisherWiley Subscription Services, Inc., A Wiley Companyen_US
dc.titleGuidelines for pediatric management of severe chronic neutropeniaen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbsecondlevelMolecular, Cellular and Developmental Biologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.subject.hlbtoplevelScienceen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumPediatric Hematology/Oncology, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherDeptartment of Medicine, University of Washington, Seattle, Washingtonen_US
dc.contributor.affiliationotherUniversity of Washington, Box 356422, 1959 NE Pacific St., Rm AA522, Seattle, WA 98195en_US
dc.identifier.pmid22237723en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90415/1/23107_ftp.pdf
dc.identifier.doi10.1002/ajh.23107en_US
dc.identifier.sourceAmerican Journal of Hematologyen_US
dc.identifier.citedreferenceZeidler C, Germeshausen M, Klein C, Welte K. Clinical implications of ELA2‐, HAX1‐, and GCSF‐receptor (CSF3R) mutations in severe congenital neutropenia. Br J Haematol 2009; 144: 459 – 467.en_US
dc.identifier.citedreferenceDale DC, Bonilla MA, Davis MW, et al. A randomized controlled phase III trial of recombinant human granulocyte colony‐stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 1993; 81: 2496 – 2502.en_US
dc.identifier.citedreferenceRosenberg PS, Zeidler C, Bolyard AA, et al. Stable long‐term risk of leukaemia in patients with severe congenital neutropenia maintained on G‐CSF therapy. Br J Haematol 2010; 150: 196 – 199.en_US
dc.identifier.citedreferenceRosenberg PS, Alter BP, Bolyard AA, et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long‐term G‐CSF therapy. Blood 2006; 107: 4628 – 4635.en_US
dc.identifier.citedreferenceDale DC, Bolyard AA, Schwinzer BG, et al. The Severe Chronic Neutropenia International Registry: 10‐year follow‐up report. Support Cancer Ther 2006; 3: 220 – 231.en_US
dc.identifier.citedreferenceDale DC, Cottle TE, Fier CJ, et al. Severe chronic neutropenia: Treatment and follow‐up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol 2003; 72: 82 – 93.en_US
dc.identifier.citedreferenceFioredda F, Calvillo M, Bonanomi S, et al. Congenital and acquired neutropenias: Consensus guidelines on therapy and follow‐up in childhood from the Neutropenia Committee of the Marrow Failure Syndrome Group of the AIEOP (Associazione Italiana Emato‐Oncologia Pediatrica). Am J Hematol 2011 [Epub ahead of print].en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
23107_ftp.pdf
Size:
40.30KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.